NEW HAVEN, Conn., Feb. 8, 2021 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or
"Biohaven"), a biopharmaceutical company with a portfolio of
innovative, late-stage product candidates today announced the
advancement of several important steps that underscore the
company's commitment to sound Environmental, Social and Governance
("ESG") practices.
Maximizing long-term shareholder value and managing resources
responsibly remains a key driving force for Biohaven's ESG
strategy, with the Company dedicated to bringing innovative
medicines forward for patients and to grow value for investors
while maintaining an efficient and high-performing culture.
The Company's Board of Directors has recently designated its
Nominating & Governance Committee (the "N&G Committee") to
oversee a management ESG Working Group, responsible for evaluating,
recommending and implementing policies, procedures and projects
focused on the ESG impacts of the Company's operations, strategy,
policies and procedures. The N&G Committee plans to meet
periodically with the ESG Working Group to get updates and provide
direction on the Company's strategy, initiatives and policies
concerning ESG matters.
The Company also announced in January that Maryellen McQuade joined as Chief Talent and
Sustainability Officer. Ms. McQuade joins Biohaven from Novo
Nordisk where she was Corporate Vice President of Human Resources,
and she has previously held leadership and other roles in human
resources with Glaxo SmithKline, Novartis Pharmaceuticals, and
Bristol-Myers Squibb. Ms. McQuade has deep expertise in talent
acquisition, managerial development, and driving culture change and
employee engagement efforts globally. She will work with the
Company's leadership team to continue to strengthen Biohaven's
commitment to empowering and developing employees and advance the
corporate ESG sustainability efforts for the ESG Working Group.
Full bio for Ms. McQuade can be found here at
www.biohavenpharma.com.
Vlad Coric, M.D., Chief Executive
Officer of Biohaven commented, "We're thrilled with Maryellen
joining our leadership team as there is natural synergy between
talent and sustainability strategies. We know that employees want
to work for companies that have sustainability and the social
mission of our Company top of mind. And the elements that make a
company sustainable also drive employee engagement, empowerment and
ultimately contribute to more effective performance. Maryellen is
known for her creative thinking, ability to break down complex
problems and calm leadership style – we are fortunate to have her
in the role as our first Chief Talent and Sustainability
Officer."
Biohaven has recently published an ESG Highlights report in an
effort to increase transparency of the Company's capabilities, the
report can be accessed on the Company's Investor page. This
initial disclosure is anticipated to be followed by a comprehensive
ESG report to be published in mid-2021.
Maryellen McQuade added, "I am
excited to join Biohaven where talent and sustainability are
understood as key enablers to the Company strategy. Biohaven is
known for its entrepreneurial approach, and I look forward to
applying that energy to sustainability, an area that is prime for
innovation."
About Biohaven
Biohaven is a commercial-stage
biopharmaceutical company with a portfolio of innovative,
best-in-class therapies to improve the lives of patients with
debilitating neurological and neuropsychiatric diseases, including
rare disorders. Biohaven's neuroinnovation portfolio includes
FDA-approved NURTEC® ODT (rimegepant) for the acute treatment of
migraine and a broad pipeline of late-stage product candidates
across three distinct mechanistic platforms: CGRP receptor
antagonism for the acute and preventive treatment of migraine;
glutamate modulation for obsessive-compulsive disorder and
spinocerebellar ataxia; and myeloperoxidase (MPO) inhibition for
multiple system atrophy and amyotrophic lateral sclerosis. More
information about Biohaven is available at
www.biohavenpharma.com.
Forward-Looking Statements
This news release includes
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements involve substantial risks and uncertainties, including
statements that are based on the current expectations and
assumptions of the Company's management. All statements, other than
statements of historical facts, included in this press release
regarding the Company's business and product candidate plans and
objectives (including ESG objectives) are forward-looking
statements. Forward-looking statements include those related to the
Company's ESG strategies and objectives and its ability to achieve
those objectives. The use of certain words, including "believe",
"continue", "may", "on track", "expects" and "will" and similar
expressions, are intended to identify forward-looking statements.
Various important factors could cause actual results or events to
differ materially from those that may be expressed or implied by
our forward-looking statements. Additional important factors to be
considered in connection with forward-looking statements are
described in the "Risk Factors" section of Biohaven's Annual Report
on Form 10-K filed with the Securities and Exchange Commission
on February 26, 2020 and Biohaven's Quarterly Report on
Form 10-Q for the quarter ended September 30, 2020 filed
with the Securities and Exchange Commission on November 9,
2020. The forward-looking statements are made as of this date and
Biohaven does not undertake any obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
NURTEC and NURTEC ODT are registered trademarks of Biohaven
Pharmaceutical Ireland DAC.
Biohaven Contact
Dr. Vlad
Coric
Chief Executive Officer
Vlad.Coric@biohavenpharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biohaven-provides-update-on-esg-practices-301223645.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.